title: Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension.
abstract: The long-term effects (9 weeks) on renal hemodynamics of the new calcium entry blocker isradipine (PN 200-110) were assessed in 20 middle-aged male patients with essential hypertension. The study was double-blind placebo-controlled with a crossover design. Isradipine or placebo tablets were titrated from 2.5, 5, and 7.5 mg b.i.d. every 3rd week to achieve a diastolic blood pressure of less than or equal to 90 mm Hg. The renal parameters were assessed 2-4 h after dosing. Despite a decrease in diastolic blood pressure (91 vs. 104 mm Hg, p less than 0.001) the renal plasma flow increased (465 vs. 394 ml/min, p less than 0.05). The glomerular filtration rate was unchanged and the filtration fraction was reduced (0.21 vs. 0.23, p less than 0.05). The plasma renin activity increased (0.71 vs. 0.51, p less than 0.05). The patients probably did not retain sodium because the body weight was unchanged. Rather, long-term treatment with isradipine was associated with a repetitive postdose increase in natriuresis (0.45 vs. 0.34 mmol/min, p = 0.06).
authors: Department of Medicine I, Sahlgren's Hospital, University of Gothenburg, Sweden.
authors: B
authors: B
authors: Persson
authors: M
authors: M
authors: Wysocki
authors: O K
authors: OK
authors: Andersson
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D012079:Renal Circulation / Q000187:drug effects*; D012083:Renin / Q000097:blood
chemical_list: D002121:Calcium Channel Blockers; D011725:Pyridines; D012083:Renin; D017275:Isradipine